Endo “continues to be encouraged” that downward pricing pressures the company has experienced in the US generic retail market “over the past few years appear to be stabilising”, president and chief executive officer Paul Campanelli has said.
Endo encouraged on US pricing condition
Endo “continues to be encouraged” that downward pricing pressures the company has experienced in the US generic retail market “over the past few years appear to be stabilising”, president and chief executive officer Paul Campanelli has said.
More from Earnings
• By
Generics Bulletin previews the most noteworthy and anticipated events for May 2025.
• By
Despite industry-wide uncertainty surrounding the Trump administration’s interest in pharma-focused tariffs, Hikma has maintained its guidance for the 2025 financial year.
• By
Samsung Bioepis has revealed first-quarter figures that reflect recent launches driving growth for the Korean biosimilars developer.
• By
Partnering opportunities, paused marketing, approvals, litigations, and many more. Formycon sets out the agenda for 2025, after seeing a bumpy start to the year.
More from Business
• By
As its need for development resources declines, Iconovo is cutting staff to save money as it moves to the commercialization stage for its portfolio of off-patent inhaled products.
• By
Amid several insights into its expectations of biosimilar competition in 2025, Roche has confirmed the total amount it anticipates being shaved from its top line this year.
• By
Despite industry-wide uncertainty surrounding the Trump administration’s interest in pharma-focused tariffs, Hikma has maintained its guidance for the 2025 financial year.